MONTREAL, CANADA AND ANTONY, FRANCE -- (MARKET WIRE) -- January 09, 2007 -- Paladin Labs Inc. (TSX: PLB) and Stallergenes SA announced today that they have entered into a Canadian development, promotion and distribution agreement for Oralair™, Stallergenes’ allergen extract immunotherapy sublingual tablets. Stallergenes and Paladin plan to submit the first product under this agreement, Oralair™ Grasses, for Canadian regulatory approval in 2007.
